Grants and Contributions:
Title:
COVID19 T-cell testing opportunities
Agreement Number:
957327
Agreement Value:
$42,900.00
Agreement Date:
Oct 1, 2020 - May 31, 2021
Description:
Growing evidence suggests that T-cell immunity against the virus is long-lasting and protective against re-infection. ChipCare is investigating a potential assay that will help identify individuals who have been exposed to a SARS corona virus in the past and may therefore have immunity to SARS-CoV2. The purpose of this project is to establish the clinical need, research appropriate markers, define the market opportunity and requirements for such an assay and to assess the suitability of such an assay for use in point-of-care settings using ChipCare’s platform.
Organization:
National Research Council Canada
Expected Results:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Location:
Toronto, Ontario, CA M5V 3B1
Reference Number:
172-2020-2021-Q3-957327
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
801903295
Recipient Type:
For-profit organization
Additional Information:
This agreement has been amended 1 time(s). The end date of this agreements has been modified by 105 days.
Amendment Date
Jan 15, 2021
Recipient's Legal Name:
ChipCare Corporation
Federal Riding Name:
Spadina--Fort York
Federal Riding Number:
35101
Program:
Industrial Research Assistance Program – Contributions to Firms
Program Purpose:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Coverage:
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.
NAICS Code:
33911
Amendments: